Alpha Tau reports Q2 2026 results and corporate update
The company reported a $68.8 million net loss, $104.8 million cash balance, and Tolmar collaboration for prostate cancer, with multiple clinical milestones.
See the latest news and media coverage for Alpha Tau. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical-stage oncology company developing alpha radiation therapy
alphatau.comLast updated
In short: Alpha Tau advanced its clinical oncology pipeline, secured a strategic prostate cancer partnership, and pursued a dual listing on TASE.
The company reported a $68.8 million net loss, $104.8 million cash balance, and Tolmar collaboration for prostate cancer, with multiple clinical milestones.
The company will offer ordinary shares on the Tel Aviv Stock Exchange and become dual-listed with Nasdaq, with trading expected under symbol DRTS and Hebrew symbol דרטס.
Median overall survival of 18.2 months and progression-free survival of 5.4 months were observed, with no serious adverse events.
The combination of Alpha DaRT and pembrolizumab met its success criterion in a Simon two-stage design, with all nine evaluable patients responding, including four complete responses.
- Groundbreaking interim results from the U.S. recurrent glioblastoma REGAIN trial demonstrated 100% local disease control and a 67% complete response rate, followed by FDA...
Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the...
In July 2026, Alpha Tau Medical reported positive podium-presented data from a single-center trial showing that its Alpha DaRT device combined with pembrolizumab achieved a...
Podium presentation at the American Head and Neck Society (AHNS) 12th International Conference on Head and Neck Cancer to report results from a...
Track Alpha Tau and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.